Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Human monoclonal [CV1] to SARS-CoV-2 Spike Ectodomain - BSA and Azide free
  • Suitable for: Indirect ELISA

Overview

  • Product name

    Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free
    See all SARS-CoV-2 Spike Ectodomain primary antibodies

  • Description

    Human monoclonal [CV1] to SARS-CoV-2 Spike Ectodomain - BSA and Azide free

  • Host species

    Human

  • Tested applications

    Suitable for: Indirect ELISAmore details

  • Immunogen

    Tissue, cells or virus. This information is proprietary to Abcam and/or its suppliers.

  • General notes

    CV1 antibody cross-reacts with SARS-CoV-2 Spike Ectodomain (including S1 domain), but not with SARS-CoV-2 Spike RBD. CV1 does not demonstrate significant neutralising ability in in-direct ELISA, measuring competitive binding of CV1 to SARS-CoV-2 Spike RBD in the presence of human ACE2

    Please note: This antibody was first isolated as an IgG1 lambda subclass. During the cloning process for the recombinant product, this was converted to an IgG1 kappa subclass, although the light chain variable region is still of the lambda subclass.

    This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.

    ab277514 is the carrier-free version of ab277512. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with

    ab277514 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

Properties

Images

  • Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)
    Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)

    This data was produced using the same clone but in a different formulation, ab277512.

    Indirect ELISA showing ab277512 (CV1) binding to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)). Plates were coated with 100ng/well ab272105 and binding of ab277512 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)
    Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)

    This data was produced using the same clone but in a different formulation, ab277512.

    Indirect ELISA showing ab277512 (CV1) binding to purified His-tagged SARS-CoV2-RBD. Plates were coated with 100ng/well purified protein and binding of ab277512 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)
    Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)

    This data was produced using the same clone but in a different formulation, ab277512.

    Indirect competition ELISA showing competitive binding of ab277512 (CV1) to purified Fc-tagged SARS-CoV2-RBD in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well SARS-CoV2-RBD and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)
    Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)

    This data was produced using the same clone but in a different formulation, ab277512.

    Indirect competition ELISA showing competitive binding of ab277512 (CV1) to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well ab272105 and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)
    Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] - BSA and Azide free (ab277514)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

© 2021 Astana Biomed Group LLP. All rights reserved.